clorazepate
Adjunctive therapy • Brands: TRANXENE
Last reviewed: 2025-12-30
General information
- Class: Adjunctive therapy
- Common US brands: TRANXENE
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Benzodiazepine prodrug; positive allosteric modulator of GABA-A receptors (via nordiazepam).
Metabolism & Half‑life
- Metabolism: Hepatic metabolism (prodrug → nordiazepam)
- Half‑life: Single-dose range 40–50 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- Clorazepate dipotassium tablets prescribing information — DailyMed (2025)
- ASAM guideline on benzodiazepines — Journal of Addiction Medicine (2020)
- Evidence-based pharmacological treatment of anxiety disorders — Depression and Anxiety (2014)
- Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care — International Journal of Psychiatry in Clinical Practice (2012)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management — Journal of Addiction Medicine (2020)